Children and adolescents who experience traumatic brain injury may face lasting mental and physical health challenges long after the initial injury, according to a new study published in JAMA Network Open. Researchers also found that strong family resilience may help reduce the risk of some long-term psychological effects. The study, led by investigators at Nationwide…
Category: Paedatric Neurology
Landmark FDA approval expands Ocrevus use to children with RRMS
The US Food and Drug Administration (FDA) has approved Ocrevus (ocrelizumab) for children aged 10 years and older with relapsing-remitting multiple sclerosis (RRMS), marking only the second therapy formally approved for paediatric MS in the United States. The decision applies to children and adolescents weighing at least 25kg and is being described by Genentech as…
